Corporate Profile

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 trials that is being developed for the treatment of Demodex blepharitis.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

SEC Filings

Filing date Description Form

Initial filing by director officer or owner of more than ten percent.

3

Initial filing by director officer or owner of more than ten percent.

3

Initial filing by director officer or owner of more than ten percent.

3